TECHNOLOGY

Pipeline

Moogene Medi's disease-specific non-viral delivery system is used in treatment programs to overcome incurable diseases.

  • image

    Topical Treatment for Hair Loss

    We have developed a novel microbubble-nanocarrier system for effective transdermal drug delivery. Based on this technology, we are developing a treatment that suppresses the expression of the enzyme that causes male hair loss.

    READ MORE


    마이크로 버블.png

    Topical Treatment for Hair Loss

                               

    Existing hair loss medication like finasteride and other drugs of the same family can trigger hormonal changes and result in a number of systemic side effects including feminization, depression, etc.

     

                                                          

    Localized drug delivery to the scalp is the ideal treatment method that would mitigates side effects, but conventional topical treatment reduces the efficacy of the drug.

     

      

    To overcome the limitation of the existing hair loss medication (low skin penetration efficiency), Moogene Medi is developing a topical hair loss treatment using microbubble technology.

     

     

        

    We expect our treatment to raise the effectiveness of topical delivery while minimizing side effects to the body.

     

     

     

                               

    Reference

     1. "탈모 치료용 약물이 봉입된 나노 리포좀-마이크로버블 결합체 및 이를 함유하는 탈모 개선 또는 치료용 조성물" 대한민국 특허 KR1020180069736

    (Read More)

     

    2. J. Y. Ryu, E. Won, H. Lee, J. H. Kim, H. P. Kim, T. –J. Yoon*, “Ultrasound-activated particles as CRISPR/Cas9 delivery system for androgenic alopecia therapy”, Biomaterials, 2020, 232, 119736      

         

    (Read More                                      


          

     

  • image

    Drug-resistant colorectal cancer treatment

    We are developing a therapy for colorectal cancer patients who have the KRAS mutation which renders existing anticancer drugs ineffective.

    READ MORE



    그림 6ㅌㄱ6.png

    Development of treatment for patients with KRAS-mutated colorectal cancer


                               

    Existing metastatic colorectal cancer drug Cetuximab can only treat colorectal cancer patients without KRAS mutation, and continuous medication will induce the KRAS mutation in 60-80% of patients who bore wild-type KRAS gene initially.

     

                             

    Moogene Medi has developed a novel nanoliposomal carrier system which contains sgRNA/Cas9 protein complexes and can be delivered to the target cancer cells to suppress the mutant KRAS gene. We have proven our technology to be effective in treating drug-resistant colorectal cancer.

     

     

     

                           Moogene Medi’s gene therapy suppresses the KRAS mutation at a fundamental basis. Our aim is not only to cure colorectal cancer, but also to achieve improve efficacy and reduce side effects gene therapies in general by specifically targeting various tumors.

     

     

     

     

     

                                Reference

                          1. Gene editing particel system as a therapeutic approach for drug-resistant colorectal cancer. Nano Research 13, 1578~1585 (2020) 

     

                            (Read More) 

     

                          2. Nano-Liposome carrier composition containing hybrid of Cas9 protein and guide RNA. US20180193269A1   

     

                            (Read More) 

     

                          3. Cas9 단백질, KRAS 유전자의 발현을 억제하는 가이드 RNA 및 양이온성 폴리머의 복합체가 봉입된 나노 리포좀 전달체 조성물 또는 이를 함유하는 KRAS 유전자 변이에 따른 항암제 저항성 대장암 치료제.  대한민국 등록 특허 10-1796036 

     

                           (Read More)

     

     

  • image

    Type 2 Diabetes Treatment

    Overexpression of an enzyme in the liver is related to Type 2 diabetes. Our platform technology allows easy delivery of gene editing materials to the liver, and fundamentally alter genetic profiles that contribute to type 2 diabetes.

    READ MORE



    당뇨 치료제 2.png

    Type 2 Diabetes Treatment


                         

    Type 2 diabetes patients have increased insulin resistance, which contributes to abnormal glucose metabolism.

     

     

    DPP4 suppressors like sitagliptin are widely used as daily medication for diabetes patients but they are toxic to the kidney, can trigger allergic reactions, and induce other side effects.

     

     

     Moogene Medi is developing a gene therapy to suppress the expression of DPP4. It is possible that patients will only need to take the medication once a year instead of every day to achieve the same effect with minimal side effects.

     

     

     

                               

    Reference

        1. Lecithin nano-liposomal particle as a CRISPR/Cas9 complex delivery system for treating type 2 diabetes. J. Nanobiotechnology, 29:17(1): 19. (2019)

     

                           (Read More) 

     

        2. Nano-liposome carrier composition containing hybrid of Cas9 protein and guide RNA"  미국특허 US10363217B2

                      

                                   (Read More) 

     

        3. "Cas9 단백질 및 가이드 RNA 혼성체를 함유하는 나노리포좀 전달체 조성물" 대한민국 특허 KR101710026B1

     

                           (Read More)